<DOC>
	<DOCNO>NCT00723086</DOCNO>
	<brief_summary>The purpose study evaluate safety docetaxel administer every 3 week repeatedly 11 cycle combination daily prednisolone metastatic hormone refractory prostate cancer .</brief_summary>
	<brief_title>Japanese Study Combined Administration Docetaxel With Prednisolone Metastatic Hormone Refractory Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<criteria>Patients complete 10 cycle docetaxel administration precede XRP6976J/2101 study wish continue docetaxel administration , alternative therapy hormone refractory prostate cancer accord Investigator 's judgment . Continuation study would detrimental patient 's wellbeing Development lifethreatening and/or toxic condition manageable symptomatic care , dose reduction , delay dose Obvious disease progression ( rise prostate specific antigen , increase â‰¥ 20 % sum measurable lesion comparison nadir value , progression nonmeasurable lesion ) Patients treated anticancer treatment study therapy completion 10 cycle study treatment XRP6976J/2101 study</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>docetaxel , prednisolone , drug combination</keyword>
</DOC>